MichaelVChioreanMD
Gastroenterology • Issaquah, WAAdvanced Endoscopic Interventional, Inflammatory Bowel Disease
Physician
Dr. Chiorean is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
751 NE Blakely Dr #3020
Ste 3020
Issaquah, WA 98029Phone+1 206-215-4250
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 2000 - 2003- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1998 - 2000
Corewell Health East Beaumont (Royal Oak)Internship, Internal Medicine, 1997 - 1998
Iuliu Hatieganu University of Medicine and PharmacyClass of 1992
Certifications & Licensure
WA State Medical License 2012 - 2025
TX State Medical License 2023 - 2023
IN State Medical License 2004 - 2013
OH State Medical License 2004 - 2007
MN State Medical License 1999 - 2005
MI State Medical License 1997 - 1998- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification HealthSentry EHR, Cerner Corporation, 2013
- Fellow (AGAF) American Gastroenterological Association, 2011
Clinical Trials
- Chromoendoscopy for Ulcerative Colitis Surveillance Start of enrollment: 2005 Dec 01
- Can CT Enteroclysis Predict the Outcome of Crohn's Disease Start of enrollment: 2007 Aug 01
- Prevalence of Lymphoma in IBD Start of enrollment: 2006 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 133 citationsEfficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative ColitisWilliam J. Sandborn, Laurent Peyrin-Biroulet, Jinkun Zhang, Michael Chiorean, Severine Vermeire
Gastroenterology. 2020-02-01 - 45 citationsIdentification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.Elisa K. Boden, Donna M. Shows, Michael Chiorean, James D. Lord
Digestive Diseases and Sciences. 2018-01-25 - 8 citationsNurse-Administered Propofol Continuous Infusion Sedation for Gastrointestinal Endoscopy in Patients Who Are Difficult to Sedate.Hyun Seok Lee, Navroop Nagra, Danielle La Selva, Richard A. Kozarek, Andrew S. Ross
Clinical Gastroenterology and Hepatology. 2021-01-01
Press Mentions
FDA Approves Zeposia for Moderate-to-Severe Ulcerative ColitisMay 28th, 2021- U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (Ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1May 27th, 2021
- One Physician's Take on CME in the Era of COVID: ACG 2020November 9th, 2020
- Join now to see all
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
